Vitamin D Treatment in Patients With Chronic Hepatitis C

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00804752
Recruitment Status : Unknown
Verified December 2008 by Hillel Yaffe Medical Center.
Recruitment status was:  Recruiting
First Posted : December 9, 2008
Last Update Posted : December 9, 2008
Information provided by:
Hillel Yaffe Medical Center

Brief Summary:
We hypothesize that patients with Ch.HCV have a low level of vitamin D, and that by raising their vitamin D levels by adding it to their standard treament of Pegylated Interferon and Ribavirin, there will be an increase in their sustained virological response.

Condition or disease Intervention/treatment Phase
Chronic Hepatitis C Drug: Adding vitamin D Drug: Vitamin D Not Applicable

Study Type : Interventional  (Clinical Trial)

Resource links provided by the National Library of Medicine

Drug Information available for: Vitamin D
U.S. FDA Resources

Arm Intervention/treatment
Experimental: Vitamin D
An addition of Vitamin D to the standard treatment
Drug: Adding vitamin D
Adding 1000IU/Vitamin D daily
Drug: Vitamin D
Addition of 1000IU/day Vitamin D

Primary Outcome Measures :
  1. To increase the sustained virological response [ Time Frame: One year ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Chronic Hepatitis C Genotype 1

Exclusion Criteria:

  • Vitamin D intoxication Renal Failure Liver Failure Malignancy

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00804752

Hillel Yaffe Medical Center Recruiting
Hadera, Israel, 38100
Contact: Saif Abu-Mouch, MD   
Principal Investigator: Saif Abu-Mouch, MD         
Sub-Investigator: Jacob Yarchovski, MD         
Sub-Investigator: Carlos Singer, MD         
Sub-Investigator: Abed El-Rauf Zeina, MD         
Sponsors and Collaborators
Hillel Yaffe Medical Center

Responsible Party: Dr. Saif Abu-Mouch, Hepatology Clinic, Hillel Yaffe Medical Center Identifier: NCT00804752     History of Changes
Other Study ID Numbers: 0040-08-HYMC
First Posted: December 9, 2008    Key Record Dates
Last Update Posted: December 9, 2008
Last Verified: December 2008

Keywords provided by Hillel Yaffe Medical Center:
Patients with Chronic Hepatitis C

Additional relevant MeSH terms:
Hepatitis A
Hepatitis C
Hepatitis, Chronic
Hepatitis C, Chronic
Liver Diseases
Digestive System Diseases
Hepatitis, Viral, Human
Virus Diseases
Enterovirus Infections
Picornaviridae Infections
RNA Virus Infections
Flaviviridae Infections
Vitamin D
Growth Substances
Physiological Effects of Drugs
Bone Density Conservation Agents